Healthcare Private Placement and M&A Transactions Review Week Ending April 20, 2025

Glycomine: The company raised $115 million of Series C venture funding in a deal led by Advent Life Sciences and CTI Life Sciences Fund on April 16, 2025. Chiesi Ventures, Novo Holdings, Sanofi Ventures, Asahi Kasei Corporate Venture Capital, Sanderling Ventures, RiverVest Venture Partners, Remiges Ventures, Abingworth and Aberdeen also participated in the round. The company is a developer of orphan drugs designed to treat rare disorders of metabolism and protein misfolding.

Attovia: The company raised $90 million of Series C venture funding in a deal led by Deep Track Capital on April 15, 2025, putting the company’s pre-money valuation at $300 million. Vida Ventures, Sanofi Ventures, Cormorant Asset Management, Frazier Healthcare Partners, venBio, Illumina Ventures, Nextech Ventures, EcoR1 Capital, Mirae Asset Capital Life Science, Goldman Sachs Asset Management and Marshall Wace also participated in the round. The company is a developer of biotherapeutics products designed for immune-mediated disease and oncology.

Lexington Medical: The company received an estimated $46.8 million of development capital from Ampersand and other undisclosed investors on April 17, 2025. The company is a manufacturer of minimally invasive surgical stapling products.

AMT Medical: The company raised $25 million of Series B venture funding in a deal led by Bender Analytical Holding on April 17, 2025. Oost NL, European Innovation Council Fund and Invest-NL also participated in the round. The company is a developer of coronary bypass technology designed to reduce bypass complications and shorten patient recovery.

HepaRegenix: The company raised EUR 21.5 million of Series C venture funding in a deal led by Vesalius Biocapital Partners on April 15, 2025. Boehringer Ingelheim Venture Fund, Novo Holdings, High-Tech Gründerfonds, and Wellington Partners also participated in the round. The company is a developer of novel therapies designed to treat acute and chronic liver diseases.

Skin Analytics: The company raised GBP 15 million of Series B venture funding in a deal led by Intrepid Growth Partners on April 16, 2025. The company is a developer of early detection  skin cancer screening technology.

Phantom Neuro: The company raised $19 million of Series A venture funding in a deal led by Ottobock on April 15, 2025, putting the company’s pre-money valuation at $34.9 million. LionBird, Draper Associates, Breakout Ventures, Time BioVentures, Rsquared, Metis Innovative, Jumpspace Ventures, Actual VC, E1 Ventures, MainSheet Ventures, and Brown Advisory also participated in the round. The company is an operator of a neurotechnology company developing human-machine interfaces and robotics for individuals with limb differences.

Yunu: The company raised an estimated $11.3 million of Series A venture funding in a deal led by Spring Mountain Capital on April 16, 2025, putting the company’s pre-money valuation at $33.7 million. The company is a developer of a cloud-based platform for managing imaging reviews in oncology trials.

SOMAVAC: The company raised $8.4 million of venture funding from undisclosed investors on April 18, 2025. The company is a developer of a sustained vacuum system designed to improve recovery after elective surgeries such as breast cancer and hernia repairs.

Healthera: The company raised GBP 5.6 million through a combination of debt and Series A venture funding in a deal led by Accelerated Digital Ventures and Committed Capital Financial Services on April 16, 2025, putting the company’s pre-money valuation at GBP 8.1 million. RYSE Asset Management, Cambridge Enterprise Investment, Future Care Capital, NHS England, Innovate UK and other undisclosed investors also participated in the round. The company is a developer of a health management application designed to connect patients with pharmacists.

Voom Medical Devices: The company raised $5 million of Series B venture funding from undisclosed investors on April 15, 2025, putting the company’s pre-money valuation at $75.5 million. The company is a manufacturer of medical equipment intended for minimally invasive surgery for the foot and ankle.

Zero Point Five Therapeutics: The company raised $4.3 million of venture funding from undisclosed investors on April 17, 2025. The company is a developer of therapeutics designed to treat soil-transmitted helminthiasis.

IBEX Innovations: The company raised GBP 3 million of venture funding from Nordson, Mercia Asset Management and North East Fund on April 17, 2025, putting the company’s pre-money valuation at GBP 6.7 million. The company is a developer of X-ray imaging software.

CND Life Sciences: The company raised $3.6 million of venture funding from undisclosed investors on April 14, 2025. The company is a developer of a medical diagnostic platform designed to detect key pathological markers in the peripheral nervous system.

AngelEye Health: The company raised $3 million of Series C venture funding from undisclosed investors on April 14, 2025, putting the company’s pre-money valuation at $47 million. The company is a developer of a tele-engagement platform designed to allow parents to become part of the care team and be proactive throughout their child’s stay in the neonatal intensive care or pediatric unit.

LightHearted AI: The company raised $3 million of venture funding from undisclosed investors on April 15, 2025. The company is a developer of a medical device intended to prevent heart-related deaths.

a:head Bio: The company raised venture funding on April 17, 2025. The company is a developer of novel drugs intended for treating brain disorders based on human cerebral organoids.

Juvenescence: The company raised an undisclosed amount of Series B venture funding from M42 and Cistern Capital on April 16, 2025, putting the company’s post-money valuation at $550 million. The company is a developer of medicines designed to extend a healthy lifespan by targeting aging mechanisms.

SmarterDx: The company raised an undisclosed amount of venture funding from New Mountain Capital and other undisclosed investors on April 14, 2025. The company is a developer of an automated pre-bill review platform designed to help hospitals realize revenue integrity.

ThirtyFiveBio: The company raised an undisclosed amount of venture funding in the form of convertible debt from AbbVie Ventures, Mayewell Capital and Canaan Partners on April 15, 2025. The company is a developer of novel genetically and pharmacologically validated protein modulators designed to treat severe gastrointestinal diseases.

iCAD / RadNet: The company reached a definitive agreement to be acquired by RadNet for $103 million on April 15, 2025. iCAD Inc is a medical technology company providing cancer detection and therapy solutions.

20/20 GeneSystems / Carmell: The company reached a definitive agreement to be acquired by Carmell  for an undisclosed amount on April 14, 2025. The company is a developer of a biomarker test intended for the early detection of cancers.

NeuroLutions / Kandu, Inc.: The company was acquired by Kandu, Inc. for an undisclosed amount on April 14, 2025. The company is a developer of neurorehabilitation devices designed to help stroke survivors restore lost arm function non-invasively.

Pelthos Therapeutics / Chromocell Therapeutics: The company reached a definitive agreement to acquire Chromocell Therapeutics through a reverse merger, resulting in the combined entity trading on the American Stock Exchange under the ticker symbol PTHS on April 17, 2025. The company is an operator of a bio-pharmaceutical business that is developing therapeutic products to help patients with unmet treatment burdens.

Starjar / PLAUD: The company was acquired by PLAUD for an undisclosed amount on April 15, 2025. The company is a developer of an AI patient intake automation software to automate patient intake and reduce the time from referral to appointment.

Taskmaster Pro / CubHub: The company was acquired by CubHub for an undisclosed amount on April 15, 2025. The company is a developer of a comprehensive Intellectual and Developmental Disabilities (IDD) practice management platform designed for IDD service providers, government agencies, and MCOs.

Theravia / Norgine: The company entered into a definitive agreement to be acquired by Norgine, via its financial sponsor Goldman Sachs Asset Management, through an LBO on April 15, 2025 for an undisclosed amount. The company is an operator of a pharmaceutical business intended to develop and commercialize treatments for rare diseases.

Tvardi Therapeutics / Cara Therapeutics: The company acquired Cara Therapeutics through a reverse merger, resulting in the combined entity trading on the NASDAQ under the ticker symbol TVRD on April 15, 2025. Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases.

Voxeleron / Voiant: The company was acquired by Voiant, via its financial sponsor DFW Capital Partners and Pelham S2K, through an LBO on April 15, 2025 for an undisclosed amount. The company is a developer of clinical information and decision support tools intended to deliver advanced image analysis solutions for applications in medicine and biology.